logo
Plus   Neg
Share
Email

Genentech Reports Positive Topline Data From Xolair Phase III Studies

Genentech, a member of the Roche Group (RHHBY), said Omalizumab has met both co-primary endpoints and key secondary endpoints across both POLYP 1 and POLYP 2 phase III trials for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP) who have not adequately responded to intranasal corticosteroids. Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in both studies. Xolair was well tolerated and the safety profile was consistent with the previous trials.

In the US., Novartis and Genentech, Inc. jointly develop and co-promote Xolair. Outside the US, Novartis markets Xolair and records its sales. The companies plan to discuss the results with the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the third quarter, Johnson & Johnson (JNJ) on Tuesday raised its earnings and sales forecast for the full year 2019. For fiscal 2019, the company now projects adjusted earnings in a range of $8.62 to $8.67 per share and adjusted operational earnings in a range... Uber Technologies Inc. (UBER) said Monday that it laid off about 350 employees across several different teams, as part of its final phase of layoffs of the process it began earlier this year. Porsche unveiled a cheaper version of its Taycan all-electric sports car, Taycan 4S. This is the third version of the sports saloon after Taycan Turbo S and Taycan Turbo launched in September. According to Porsche, Taycan 4S is now the new entry-level model in the Taycan series. The new model is available is two versions based on battery sizes.
Follow RTT
>